Prestige Consumer Healthcare (NYSE:PBH) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Prestige Consumer Healthcare (NYSE:PBH) reported quarterly earnings of $1.07 EPS, exceeding estimates by $0.10. Revenue was $274.11 million, surpassing expectations of $257.14 million, but down 3.4% year-over-year. The company updated its FY 2026 guidance to 4.540-4.580 EPS. Despite the positive earnings, PBH shares fell 2.5% to $59.85. Institutional investors hold 99.95% of the stock, with recent modifications in holdings by major firms. Analysts have mixed ratings, with a consensus rating of "Hold" and a price target of $85.33.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) released its quarterly earnings data on Thursday. The company reported $1.07 EPS for the quarter, topping analysts' consensus estimates of $0.97 by $0.10, Zacks reports. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. During the same period in the prior year, the firm posted $1.09 EPS. The business's revenue for the quarter was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare updated its FY 2026 guidance to 4.540-4.580 EPS.

Prestige Consumer Healthcare Stock Down 2.5%

PBH traded down $1.51 during trading hours on Friday, reaching $59.85. 578,048 shares of the stock traded hands, compared to its average volume of 417,609. Prestige Consumer Healthcare has a fifty-two week low of $59.51 and a fifty-two week high of $90.04. The company has a market cap of $2.95 billion, a price-to-earnings ratio of 14.05, a PEG ratio of 1.93 and a beta of 0.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The firm's fifty day simple moving average is $62.98 and its two-hundred day simple moving average is $73.18.

Institutional Trading of Prestige Consumer Healthcare

Large investors have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company's stock worth $57,601,000 after purchasing an additional 115,459 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Prestige Consumer Healthcare by 12.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,407 shares of the company's stock valued at $44,190,000 after buying an additional 63,168 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock valued at $46,997,000 after buying an additional 120,965 shares during the last quarter. Public Sector Pension Investment Board raised its stake in Prestige Consumer Healthcare by 6.2% during the second quarter. Public Sector Pension Investment Board now owns 189,134 shares of the company's stock worth $15,102,000 after acquiring an additional 11,115 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Prestige Consumer Healthcare by 25.3% in the second quarter. Jane Street Group LLC now owns 131,337 shares of the company's stock worth $10,487,000 after acquiring an additional 26,535 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PBH shares. Jefferies Financial Group dropped their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a "hold" rating for the company in a research note on Monday, October 27th. Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Oppenheimer dropped their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an "outperform" rating for the company in a research report on Tuesday, October 21st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a "buy" rating for the company in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $85.33.

View Our Latest Analysis on Prestige Consumer Healthcare

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?

Before you consider Prestige Consumer Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.

While Prestige Consumer Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here